A revolutionary new breast cancer treatment from AstraZeneca is set to transform patient care, demonstrating remarkable efficacy in reducing the risk of death and tumor progression. Named Enhertu, this drug has been shown to decrease the likelihood of these severe outcomes by 72% when compared to the existing standard treatment, Kadcyla.
Results from a significant clinical trial reveal that Enhertu significantly benefits those diagnosed with metastatic breast cancer, a serious condition where cancer cells have spread throughout the body. The phase-three trial, DESTINY-Breast03, involved 500 women whose tumors exhibited high levels of HER2 protein and had not responded to prior therapies. The findings indicated that 75.8% of participants receiving Enhertu experienced no disease progression after one year, in stark contrast to just 34.1% of those treated with Kadcyla.
“We’ve never observed such a considerable benefit in metastatic breast cancer before,” stated Michael Anderson, head of oncology at AstraZeneca. Ken Lewis, global head of research and development at Daiichi Sankyo, emphasized the early survival data, indicating that nearly all Enhertu-treated patients were alive after one year, highlighting the potential for this medication to revolutionize HER2-positive metastatic breast cancer treatment.
Susan Taylor, Executive Vice President of Oncology R&D, noted, “The results are groundbreaking. Enhertu tripled progression-free survival, demonstrating a disease control rate exceeding 95% compared to 77% for T-DM1 in DESTINY-Breast03. These unprecedented results represent a potential shift in how we treat HER2-positive metastatic breast cancer, aiming to improve the lives of more patients in earlier treatment stages.”
AstraZeneca, known for its collaboration with Oxford University on a widely used COVID vaccine, acquired Enhertu through a $6.9 billion agreement with Daiichi-Sankyo, the drug’s original developer. The company hopes to explore Enhertu’s use in earlier-stage breast cancer patients, with the aim of treating and potentially curing the disease. Currently, it is administered as a third-line option for women with advanced HER2-positive breast cancer, who have already undergone two unsuccessful treatments.
For more information, check out this related blog post for additional insights. If you’re considering home insemination options, visit Make a Mom, an authority on the topic. Another excellent resource can be found at Resolve.org for further guidance on pregnancy and home insemination.
Summary
AstraZeneca’s new drug Enhertu shows a remarkable 72% reduction in the risk of death or tumor progression in patients with metastatic breast cancer compared to the standard treatment, Kadcyla. The phase-three DESTINY-Breast03 trial highlights significant benefits for patients, paving the way for a potential shift in treatment protocols.
Leave a Reply